Food and Drug Administration
Cardiovascular and Renal Drugs Advisory Committee
July 19, 2002
Slides
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Omapatrilat in the Treatment of Hypertension, Dr. Anthony Waclawski, PhD, Pharmaceutical Research Institute htm ppt
Efficacy and Safety, Dr. Elliott Levy, MD, Pharmaceutical Research Institute htm ppt
Overture, Dr. Milton Packer, MD, FACC, Columbia Presbyterian Medical Ctr. htm ppt
Clinician's Perspective, Dr. Henry Black, MD FACP, Rush-Presbyterian-St. Luke' Medical Ctr. htm ppt
Additional Information htm ppt